MARKET

TBPH

TBPH

Theravance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.92
+0.53
+2.88%
Pre Market: 18.92 0 0.00% 08:00 03/04 EST
OPEN
18.47
PREV CLOSE
18.39
HIGH
19.13
LOW
18.12
VOLUME
1
TURNOVER
--
52 WEEK HIGH
31.35
52 WEEK LOW
14.48
MARKET CAP
1.22B
P/E (TTM)
-4.2258
1D
5D
1M
3M
1Y
5Y
Neprilysin Market Size by Region 2021, Latest Trends, Key Players with Growth Rate, Total Revenues, Impact of COVID-19 on Global Industry and Recovery by 2027
Mar 04, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Neprilysin Market” report analysis...
The Express Wire · 5h ago
Theravance Biopharma to Participate in an Upcoming Investor Conference
, /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will participate in a pre-recorded Fireside Chat at th...
PR Newswire - PRF · 2d ago
Global COPD Therapeutics Market 2020 Size, Revenue, Growth Rate, Restraints, Forecast Analysis by 2025
Mar 01, 2021 (CDN Newswire via Comtex) -- Newly added by MarketsandResearch.biz study on Global COPD Therapeutics Market Growth (Status and Outlook)...
CDN Newswire · 2d ago
DJ Theravance Biopharma Is Maintained at Overweight by Morgan Stanley
Dow Jones · 2d ago
DJ Theravance Biopharma Price Target Cut to $30.00/Share From $31.00 by Morgan Stanley
Dow Jones · 2d ago
Morgan Stanley Maintains Overweight on Theravance Biopharma, Lowers Price Target to $30
Morgan Stanley analyst Vikram Purohit maintains Theravance Biopharma (NASDAQ:TBPH) with a Overweight and lowers the price target from $31 to $30.
Benzinga · 2d ago
COPD Therapeutics Market Growth Factors, Applications, Regional Analysis, Key Players and Forecasts2020-2027 By Ameco Research
pune, India, Thu, 25 Feb 2021 01:12:33 / Comserve Inc. / -- COPD Therapeutics market to help players in achieving a strong market position. Buyers of the...
Comserve · 02/25 06:13
Antibiotic Resistance Market is expected to Reached 13,146 million at a 5.8% From 2019-2025 | Global Industry Trends, Size, Share, Growth, Top Leaders, Revenue and Comprehensive Analysis
Feb 24, 2021 (Heraldkeepers) -- Antibiotic Resistance Market Analysis The antibiotic resistance market is likely touch USD 13,146 million at a 5.8% CAGR...
Heraldkeepers · 02/25 04:47
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TBPH. Analyze the recent business situations of Theravance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TBPH stock price target is 31.88 with a high estimate of 42.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 188
Institutional Holdings: 72.52M
% Owned: 112.73%
Shares Outstanding: 64.33M
TypeInstitutionsShares
Increased
32
2.84M
New
41
-790.35K
Decreased
32
1.38M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.99%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Chief Executive Officer/Director
Rick Winningham
Chief Financial Officer/Senior Vice President
Andrew Hindman
Corporate Executive
Ann Brady
Executive Vice President/General Counsel/Secretary
Bradford Shafer
Senior Vice President
Brett Haumann
Senior Vice President
.. ..
Senior Vice President
Frank Pasqualone
Senior Vice President
Kenneth Pitzer
Senior Vice President
Vijay Sabesan
Senior Vice President
Philip Worboys
Lead Director/Independent Director
William Young
Director
Robert Gunderson
Independent Director
Laurie Alsup
Independent Director
Eran Broshy
Independent Director
Burton Malkiel
Independent Director
Dean Mitchell
Independent Director
Susan Molineaux
Independent Director
Donal O'Connor
Independent Director
Deepika Pakianathan
Independent Director
George Whitesides
No Data
  • All
  • Financials
  • Insiders
More
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Webull offers kinds of Theravance Biopharma Inc stock information, including NASDAQ:TBPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TBPH stock methods without spending real money on the virtual paper trading platform.